Neuroendocrine Tumor Research Funding
The Neuroendocrine Tumor Research Foundation (NETRF) was founded by a patient, Nancy Lindholm, in 2005, with the mission to discover cures and more effective treatments for neuroendocrine tumors (NETs). Since 2005, we have funded over 60 research projects, totaling more than $26 million in NET research.
As the leading funder of neuroendocrine tumor research, our goal is to transform the NET research landscape by supporting cutting-edge basic, translational, and clinical research, recruiting new investigators to NETs, and fostering a collaborative, scientific community that works together to understand the origin and development of neuroendocrine tumors, in an effort to create more effective therapies.
We are grateful to the generous gifts from our donors that make our work possible.
The latest in NET News
NETRF’s Director of Research John Kanki, PhD, provides an update on the status of ongoing NETRF-funded research studies during COVID-19.
NETRF reports progress in the development of neuroendocrine tumor cell lines to help eliminate a decades-old obstacle in laboratory research. To stimulate progress in NET cell lines, NETRF established a Cell Line Prize, funded cell line research, and launched a collaboration with a nationally known research institute. Each of these initiatives has succeeded in establishing NET cell lines.
Research to Advance Neuroendocrine Tumor Treatment The Neuroendocrine Tumor Research Foundation (NETRF) today announced $3.5